Multiple Sclerosis Risk Loci Correlate with Cervical Cord Atrophy and May Explain the Course of Disability

Overview

Journal Neurogenetics

Specialty Neurology

Date 2015 Jan 27

PMID 25620546

Citations 9

Authors

Denis A Akkad

Barbara Bellenberg

Sarika Esser

Florian Weiler

Jorg T Epplen

Ralf Gold

Carsten Lukas

Aiden Haghikia

Affiliations

Soon will be listed here.

Abstract

Genome-wide association studies (GWAS) underscore the genetic basis of multiple sclerosis (MS); however, only few of the newly reported genetic variations relevant in MS have been replicated or correlated for clinical/paraclinical phenotypes such as spinal cord atrophy in independent patient cohorts. We genotyped 141 MS patients for 58 variations reported to reach significance in GWAS. Expanded disability status scale (EDSS) and disease duration (DD) are available from regular clinical examinations. MRI included sagittal high-resolution 3D T1-weighted magnetization-prepared rapid acquisition gradient echo of the cervical cord region used for volumetry. Due dependency of mean upper cervical cord area (MUCCA) with EDSS and/or DD, correction operations were performed compensating for EDSS/DD. We assessed each MS risk locus for possible MUCCA association. We identified twelve risk loci that significantly correlated with MUCCA. For nine loci-BATF, CYP27B1, IL12B, NFKB1, IL7, PLEK, EVI5, TAGAP and nrs669607-patients revealed significantly higher degree of atrophy; TYK2, RGS1 and CLEC16A revealed inverse effects. The weighted genetic risk score over the twelve loci showed significant correlation with MUCCA. Our data reveal a risk gene depending paraclinical/clinical phenotype. Since MUCCA clearly correlates with disability, the candidates identified here may serve as prognostic markers for disability progression.

Citing Articles

The role of BATF in immune cell differentiation and autoimmune diseases.

Wang X, Hong Y, Zou J, Zhu B, Jiang C, Lu L Biomark Res. 2025; 13(1):22.

PMID: 39876010 PMC: 11776340. DOI: 10.1186/s40364-025-00733-x.

Adaptive and Innate Immunity Are Key Drivers of Age at Onset of Multiple Sclerosis.

Misicka E, Huang Y, Loomis S, Sadhu N, Fisher E, Gafson A Neurol Genet. 2024; 10(3):e200159.

PMID: 38817245 PMC: 11139017. DOI: 10.1212/NXG.0000000000200159.

Combination of Genomic and Transcriptomic Approaches Highlights Vascular and Circadian Clock Components in Multiple Sclerosis.

Scapoli C, Ziliotto N, Lunghi B, Menegatti E, Salvi F, Zamboni P Int J Mol Sci. 2022; 23(1).

PMID: 35008743 PMC: 8745220. DOI: 10.3390/ijms23010310.

Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS.

Sinnecker T, Granziera C, Wuerfel J, Schlaeger R Curr Treat Options Neurol. 2018; 20(6):17.

PMID: 29679165 DOI: 10.1007/s11940-018-0504-7.

The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Mahajan K, Ontaneda D Neurotherapeutics. 2017; 14(4):905-923.

PMID: 28770481 PMC: 5722766. DOI: 10.1007/s13311-017-0561-8.

References

Evangelou N, DeLuca G, Owens T, Esiri M . Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain. 2004; 128(Pt 1):29-34. DOI: 10.1093/brain/awh323. View

Lill C, Liu T, Schjeide B, Roehr J, Akkad D, Damotte V . Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects. J Med Genet. 2012; 49(9):558-62. DOI: 10.1136/jmedgenet-2012-101175. View

Sawcer S, Hellenthal G, Pirinen M, Spencer C, Patsopoulos N, Moutsianas L . Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476(7359):214-9. PMC: 3182531. DOI: 10.1038/nature10251. View

Healy B, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C . HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010; 75(7):634-40. PMC: 2931768. DOI: 10.1212/WNL.0b013e3181ed9c9c. View

De Jager P, Chibnik L, Cui J, Reischl J, Lehr S, Simon K . Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol. 2009; 8(12):1111-9. PMC: 3099419. DOI: 10.1016/S1474-4422(09)70275-3. View

McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-7. DOI: 10.1002/ana.1032. View

Roxburgh R, Seaman S, Masterman T, Hensiek A, Sawcer S, Vukusic S . Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005; 64(7):1144-51. DOI: 10.1212/01.WNL.0000156155.19270.F8. View

Shahijanian F, Parnell G, McKay F, Gatt P, Shojoei M, OConnor K . The CYP27B1 variant associated with an increased risk of autoimmune disease is underexpressed in tolerizing dendritic cells. Hum Mol Genet. 2013; 23(6):1425-34. DOI: 10.1093/hmg/ddt529. View

Rocca M, Horsfield M, Sala S, Copetti M, Valsasina P, Mesaros S . A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology. 2011; 76(24):2096-102. DOI: 10.1212/WNL.0b013e31821f46b8. View

10.

Lukas C, Knol D, Sombekke M, Bellenberg B, Hahn H, Popescu V . Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014; 86(4):410-8. DOI: 10.1136/jnnp-2014-308021. View

11.

Imrell K, Landtblom A, Hillert J, Masterman T . Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct. Neurology. 2006; 67(6):1062-4. DOI: 10.1212/01.wnl.0000237343.93389.35. View

12.

Sawcer S, Ban M, Wason J, Dudbridge F . What role for genetics in the prediction of multiple sclerosis?. Ann Neurol. 2010; 67(1):3-10. PMC: 2830384. DOI: 10.1002/ana.21911. View

13.

Oksenberg J, Baranzini S . Multiple sclerosis genetics--is the glass half full, or half empty?. Nat Rev Neurol. 2010; 6(8):429-37. DOI: 10.1038/nrneurol.2010.91. View

14.

Gourraud P, McElroy J, Caillier S, Johnson B, Santaniello A, Hauser S . Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann Neurol. 2011; 69(1):65-74. PMC: 3511846. DOI: 10.1002/ana.22323. View

15.

Liguori M, Healy B, Glanz B, Khoury S, Moscufo N, Weiner H . HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun. 2010; 12(3):183-90. DOI: 10.1038/gene.2010.58. View

16.

Lukas C, Sombekke M, Bellenberg B, Hahn H, Popescu V, Bendfeldt K . Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology. 2013; 269(2):542-52. DOI: 10.1148/radiology.13122566. View

17.

Mowry E, Carey R, Blasco M, Pelletier J, Duquette P, Villoslada P . Multiple sclerosis susceptibility genes: associations with relapse severity and recovery. PLoS One. 2013; 8(10):e75416. PMC: 3793991. DOI: 10.1371/journal.pone.0075416. View

18.

van Oosten B, Barkhof F, Truyen L, Boringa J, Bertelsmann F, von Blomberg B . Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996; 47(6):1531-4. DOI: 10.1212/wnl.47.6.1531. View

19.

Gregory A, Dendrou C, Attfield K, Haghikia A, Xifara D, Butter F . TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 2012; 488(7412):508-511. PMC: 4268493. DOI: 10.1038/nature11307. View